Eltrombopag (Revolade®)

Assessment Status Rapid review complete
Drug Eltrombopag
Brand Revolade®
Indication For adult patients with chronic hepatitis C virus (HCV) infection for the treatment of thrombocytopenia, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy
Assessment Process
Rapid review commissioned 10/01/2014
Rapid review completed 13/02/2014
Rapid review outcome Full Pharmacoeconomic Evaluation not Recommended.